Interestingly, among 7 non-apocrine samples showing HMGCS2+/AR+/ER-/PR- profile 6 were HER2+ (86%; remaining sample was classified as a borderline) (Table S5), whereas in the entire cohort of 203 samples, HER2 positives were observed in 58 samples (28,6%), indicating that among tumors outside apocrine carcinoma the phenotype HMGCS2+/AR+/ER-/PR- is correlated with HER2 amplification (p<0.003). This evidence concerns the gene HMGCS2 and apocrine adenocarcinoma.